Clinical and Biologic Outcomes Following the Administration of Hydroxyurea to Homozygote Sickle Cell Patients in Two Health Facilities of Yaounde
B. Chetcha Chemegni, A. V. Kouam Kaping, I. Ngosso Tetanyé, A. Bodieu Kenmegne, L. Kouemeni, G. Ngouefo, E. K. Ola Bamzok, Tetanye Ekoe & L. Kaptué Noche · Asian Hematology Research Journal · 2018
Sickle cell disease is the most frequent genetic disease worldwide with high mortality and morbidity rates. Several therapeutic medications have been put in place amongst which hydroxurea, an antineoplastic for which the clinical-biologic benefits for the patients have been estab...
Open access
Research Article